Abstract Details

Title Peginterferon beta-1a every 2 weeks demonstrated better outcomes than glatiramer acetate (GA) once daily in patients with relapsing-remitting multiple sclerosis (RRMS): propensity score matching (PSM) of phase 3 data from ADVANCE and CONFIRM

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-068

Objective Compare subcutaneous peginterferon beta-1a 125 mcg every 2 weeks with subcutaneous GA 20 mg/mL once daily on clinical efficacy endpoints at 2 years in patients from the ADVANCE and CONFIRM trials using PSM.

Background Peginterferon beta-1a and GA are approved first-line therapies for treatment of RRMS, but head-to-head efficacy comparisons are lacking. PSM permits comparison of efficacy outcomes across trials.

Design/Methods PSM (1:1) based on key baseline characteristics was performed on 512 ADVANCE peginterferon beta-1a patients and 350 CONFIRM GA patients. For no evidence of disease activity (NEDA) analyses including MRI assessments, 510 ADVANCE and 174 CONFIRM MRI subcohort patients were matched 2:1. Outcomes included annualized relapse rate (ARR), 12-week and 24-week confirmed disability worsening (CDW), clinical-NEDA (no relapses or 12-week CDW), MRI-NEDA (no new/newly enlarging T2 or gadolinium-enhancing lesions), and overall NEDA (meeting both clinical- and MRI-NEDA criteria).

Results After 1:1 matching, 336 patients from each treatment group were included. At 2 years, peginterferon beta-1a–treated patients had a significantly lower ARR (0.20 vs 0.28; rate ratio=0.724; P=0.045), a significantly lower probability of 12-week CDW (10.0% vs 14.6%; hazard ratio=0.625; P=0.048), and a numerically lower probability of 24-week CDW (7.7% vs 10.6%; hazard ratio=0.684; P=0.171) compared with GA-treated patients. Over 2 years, clinical-NEDA was achieved by similar percentages of peginterferon beta-1a and GA patients (56.0% vs 55.1%; P=0.762). After matching, MRI-NEDA and overall NEDA analyses included 305 peginterferon beta-1a and 165 GA patients. A significantly higher percentage of peginterferon beta-1a than GA patients achieved MRI-NEDA (27.5% vs 16.4%; P=0.014) and overall NEDA (20.3% vs 11.5%; P=0.047) over 2 years.

Conclusions In this PSM analysis using data from recent phase 3 trials in RRMS patients, peginterferon beta-1a every 2 weeks showed significantly better outcomes over 2 years on ARR, CDW, and NEDA compared with GA once daily.

Authors/Disclosures
Thomas F. Scott, MD (AHN Neurology) PRESENTER	Dr. Scott has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme-Sanofi. Dr. Scott has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Serono. Dr. Scott has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Scott has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Scott has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genzyme.
	No disclosure on file
Carmen Castrillo-Viguera	Dr. Castrillo-Viguera has received personal compensation for serving as an employee of Biogen. Dr. Castrillo-Viguera has received stock or an ownership interest from Biogen.
	No disclosure on file
Maria Naylor, PhD	Dr. Naylor has received personal compensation for serving as an employee of Dyne Therapeutics. Dr. Naylor has stock in Biogen. Dr. Naylor has stock in Dyne Therapeutics.

��ɫ��

��ɫ��